Allergy

A new NIH-funded study showed that patients with atopic dermatitis may increase their risk of food allergies when they scratch their skin.

A new study from Canada found children as young as 9 months of age can safely undergo the desensitization treatment routinely.

Investigators found that peanut allergy immunotherapy was associated with a greater risk of anaphylaxis, epinephrine use, and serious adverse events compared to avoidance or placebo.

Patients who suffer from pollen allergies are likely to face more severe symptoms and longer allergy seasons as a result of global warming.

Sublingual allergy tablets are becoming a common treatment option among allergists, though they remain a back-up choice in the eyes of many physicians.

The investigative solution improved patient metrics for itching, and could be considered for FDA submission later this year.

Aimmune announced AR101 phase 3 trial reached its primary efficacy endpoint, intent to submit marketing authorization application.

The oral immunotherapy seeks approval as a treatment to reduce the risk of anaphylaxis in peanut-allergic children and adolescents following exposure to peanut.

Studies show that more than 90% of EoE patients improve symptoms with food elimination therapy. Should more patients be in touch with allergists?

This is the third indication for the biologic therapy, following its approvals for adult AD and moderate to severe asthma maintenance care.

The biologic has been previously approved for adult atopic dermatitis and uncontrolled asthma, and is being assesed for another half-dozen allergic/immunologic indications.

The first generation of food allergy treatments is nearing the market. What could be next is more individualized therapies.

What other specialties should become more involved in the network of care for allergic patients?

Is the US population having allergies diagnosed correctly, and are allergies on the rise?

The analysis of the UltIMMa 1 & 2 trials of risankizumab demonstrated efficacy and safety in the treatment of moderate-to-severe plaque psoriasis.

Investigational treatment PRN1008 demonstrated efficacy in this difficult-to-treat condition.

The phase 2 Believe-PV study observed few adverse events in patients with pemphigus vulgaris.

Though there are few treatments for pemphigus vulgaris, a rare disease, the Believe-PV trial of PRN1008 raises the possibility of a new, better option.

Investigators sought to evaluate the efficacy, safety, psychosocial impact, quality of life, adherence to and satisfaction with the treatment of dupilumab and add-on treatment.

Pediatric peanut allergy trials have proven successful. Now where do researchers look next?

What does the typical patient have to treat aside from their allergy, and what are their treatment goals?

Patients who incorporated small amounts of peanut into their diet experienced increased quality of life.

Have current guidelines been fitted to consider the future of immunotherapy research?

UNC investigators consider the role current food allergy trials may play in addressing gaps of knowledge on patient individualization.

Mothers reported breastfeeding infants who reacted to food allergen exposure via breastmilk for significantly longer than infants who did not react.